Abivax (ABVX) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $92.38, +5.00% vs the prior close of $87.98.
- Volume 1.52M shares, 1.3x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
ABVX jumps 5.0% to $92.38. Closed at $92.38, +5.00% vs the prior close of $87.98. Day range $88.03–$92.81, opened at $88.36.
ABVX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — ABVX jumps 5.0% to $92.38
- Closed at $92.38, +5.00% vs the prior close of $87.98. Day range $88.03–$92.81, opened at $88.36.
- Volume was 1.52M shares, 1.3x its 50-day average of 1.14M.
- Price is -14.3% vs its 50-day average ($107.75) and -20.4% vs its 200-day average ($116.05).
- 52-week range $69.81–$148.83; today's close sits at 29% of that range, 37.9% below the 52-week high.
Oct 14, 2026 — ABVX rises 2.0% to $87.98
- Closed at $87.98, +2.04% vs the prior close of $86.22. Day range $85.88–$89.38, opened at $86.12.
- Volume was 1.13M shares, 1.0x its 50-day average of 1.13M.
- Price is -18.8% vs its 50-day average ($108.41) and -24.3% vs its 200-day average ($116.29).
- 52-week range $69.81–$148.83; today's close sits at 23% of that range, 40.9% below the 52-week high.
Oct 13, 2026 — ABVX dips 0.8% to $86.22, a 3-month low, 3 down days in a row
- Closed at $86.22, -0.83% vs the prior close of $86.94. Day range $84.51–$86.86, opened at $85.92.
- Volume was 992.70K shares, 0.9x its 50-day average of 1.13M.
- Price is -21.0% vs its 50-day average ($109.15) and -26.0% vs its 200-day average ($116.56).
- 52-week range $69.81–$148.83; today's close sits at 21% of that range, 42.1% below the 52-week high.
- That makes 3 straight losses.
Oct 12, 2026 — ABVX dips 1.4% to $86.94, a 3-month low
- Closed at $86.94, -1.37% vs the prior close of $88.15. Day range $86.40–$87.91, opened at $87.32.
- Volume was 658.90K shares, 0.6x its 50-day average of 1.14M — lighter than usual.
- Price is -20.9% vs its 50-day average ($109.92) and -25.6% vs its 200-day average ($116.85).
- 52-week range $69.81–$148.83; today's close sits at 22% of that range, 41.6% below the 52-week high.
Oct 9, 2026 — ABVX dips 1.0% to $88.15
- Closed at $88.15, -1.01% vs the prior close of $89.05. Day range $87.39–$90.56, opened at $90.21.
- Volume was 884.90K shares, 0.8x its 50-day average of 1.15M.
- Price is -20.4% vs its 50-day average ($110.68) and -24.7% vs its 200-day average ($117.11).
- 52-week range $69.81–$148.83; today's close sits at 23% of that range, 40.8% below the 52-week high.
Oct 8, 2026 — ABVX rises 2.3% to $89.05 on 1.9x normal volume
- Closed at $89.05, +2.34% vs the prior close of $87.01. Day range $84.11–$89.10, opened at $86.70.
- Volume was 2.10M shares, 1.9x its 50-day average of 1.13M — unusually heavy trading.
- Price is -20.1% vs its 50-day average ($111.41) and -24.1% vs its 200-day average ($117.36).
- 52-week range $69.81–$148.83; today's close sits at 24% of that range, 40.2% below the 52-week high.
Oct 7, 2026 — ABVX dips 1.4% to $87.01, a 3-month low, 5 down days in a row
- Closed at $87.01, -1.37% vs the prior close of $88.22. Day range $86.00–$88.46, opened at $86.86.
- Volume was 1.39M shares, 1.2x its 50-day average of 1.12M.
- Price is -22.3% vs its 50-day average ($112.00) and -25.9% vs its 200-day average ($117.49).
- 52-week range $69.81–$148.83; today's close sits at 22% of that range, 41.5% below the 52-week high.
- That makes 5 straight losses.
Oct 6, 2026 — ABVX slides 3.8% to $88.22, a 3-month low on 1.8x normal volume
- Closed at $88.22, -3.83% vs the prior close of $91.73. Day range $87.83–$93.67, opened at $93.67.
- Volume was 2.00M shares, 1.8x its 50-day average of 1.10M — unusually heavy trading.
- Price is -21.8% vs its 50-day average ($112.75) and -25.0% vs its 200-day average ($117.63).
- 52-week range $69.81–$148.83; today's close sits at 23% of that range, 40.7% below the 52-week high.
- That makes 4 straight losses.
Oct 5, 2026 — ABVX dips 1.2% to $91.73, 3 down days in a row
- Closed at $91.73, -1.24% vs the prior close of $92.88. Day range $89.40–$92.61, opened at $92.27.
- Volume was 840.20K shares, 0.8x its 50-day average of 1.10M.
- Price is -19.2% vs its 50-day average ($113.54) and -22.1% vs its 200-day average ($117.74).
- 52-week range $69.81–$148.83; today's close sits at 28% of that range, 38.4% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — ABVX dips 2.3% to $92.88
- Closed at $92.88, -2.33% vs the prior close of $95.10. Day range $92.58–$95.82, opened at $95.82.
- Volume was 644.20K shares, 0.6x its 50-day average of 1.10M — lighter than usual.
- Price is -18.7% vs its 50-day average ($114.22) and -21.2% vs its 200-day average ($117.84).
- 52-week range $69.81–$148.83; today's close sits at 29% of that range, 37.6% below the 52-week high.
ABVX latest news & SEC filings
Every SEC filing by or about ABVX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 21, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 6, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 2, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Jul 2, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Jul 1, 2026 · Form FWP — Free writing prospectus (offering marketing material)
Free writing prospectus (offering marketing material)
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Jun 30, 2026 · Form FWP — Free writing prospectus (offering marketing material)
Free writing prospectus (offering marketing material)
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Jun 30, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Jun 30, 2026 · Form POSASR — POSASR filing
POSASR filing
Jun 29, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Things to know before you trade ABVX
- How much it moves: over the last 20 sessions the average daily move was 2.56% (largest 6.4%).
- Liquidity: about 1.39M shares (≈$128.21M) trade per day on average.
- 52-week position: $92.38 vs a range of $69.81–$148.83 (29% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 6-K Sep 21, 2026; 6-K Jul 2, 2026; 6-K Jun 29, 2026.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
ABVX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 88.36 | 92.81 | 88.03 | 92.38 | 1.52M |
| Oct 14, 2026 | 86.12 | 89.38 | 85.88 | 87.98 | 1.13M |
| Oct 13, 2026 | 85.92 | 86.86 | 84.51 | 86.22 | 992.70K |
| Oct 12, 2026 | 87.32 | 87.91 | 86.40 | 86.94 | 658.90K |
| Oct 9, 2026 | 90.21 | 90.56 | 87.39 | 88.15 | 884.90K |
| Oct 8, 2026 | 86.70 | 89.10 | 84.11 | 89.05 | 2.10M |
| Oct 7, 2026 | 86.86 | 88.46 | 86.00 | 87.01 | 1.39M |
| Oct 6, 2026 | 93.67 | 93.67 | 87.83 | 88.22 | 2.00M |
| Oct 5, 2026 | 92.27 | 92.61 | 89.40 | 91.73 | 840.20K |
| Oct 2, 2026 | 95.82 | 95.82 | 92.58 | 92.88 | 644.20K |
| Oct 1, 2026 | 96.60 | 97.12 | 93.87 | 95.10 | 1.24M |
| Sep 30, 2026 | 99.33 | 100.08 | 97.46 | 99.02 | 886.10K |
| Sep 29, 2026 | 96.97 | 99.17 | 94.40 | 98.50 | 1.63M |
| Sep 28, 2026 | 91.50 | 97.27 | 91.45 | 96.85 | 1.68M |
| Sep 25, 2026 | 94.00 | 94.16 | 90.96 | 91.06 | 1.48M |
| Sep 24, 2026 | 92.97 | 95.88 | 91.96 | 94.87 | 1.66M |
| Sep 23, 2026 | 98.30 | 98.50 | 92.57 | 94.13 | 2.63M |
| Sep 22, 2026 | 102.74 | 102.74 | 96.74 | 98.29 | 2.53M |
| Sep 21, 2026 | 105.72 | 105.72 | 102.52 | 103.45 | 973.00K |
| Sep 18, 2026 | 107.00 | 107.18 | 103.89 | 105.04 | 876.00K |
About Abivax
Abivax (ABVX) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in PARIS. State of incorporation: France. Fiscal year ends December 31. SEC CIK 1956827.
ABVX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| No Form 3/4/5 filings by this group in the last 12 months. | ||
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| No Form 3/4/5 filings by this group in the last 12 months. | ||
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
ABVX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| No annual XBRL figures available (foreign filers often report on Form 20-F). | ||||
Latest balance sheet: total assets $—, total liabilities $—, cash $—.
ABVX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| No 8-K earnings releases in recent filings. | ||
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on ABVX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.